This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Treatment with CM313, a novel anti-CD38 monoclonal antibody, can result in targeted clearance of CD38-positive cells, including plasma cells. We conducted a phase 1–2, open-label study to ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

DelveInsight's Anti-CD38 mAb Market Insights report includes a comprehensive understanding of current treatment practices, emerging anti-CD38 mAb, market share of individual therapies, ...

So the IMROZ clinical trial, which compared isatuximab, an anti-CD38 monoclonal antibody, bortezomib, lenalidomide, and dexamethasone—so a quadruplet regimen containing anti-CD38 antibody plus ...

Anti-CD38 antibodies (help the immune system kill cancer cells) Your health care provider will review your medical history and decide if Tecvayli is right for you. One clinical study ...

Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggests the anti-CD38 antibody could still “transform treatment” of primary immune ...

Daratumumab plus a standard triplet improved minimal residual disease negativity rates in patients with transplant-ineligible multiple myeloma. The quadruplet also improved rates of complete ...

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...